Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
Sponsor: Wake Forest University Health Sciences
Summary
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
86
Start Date
2022-01-04
Completion Date
2026-04
Last Updated
2026-01-06
Healthy Volunteers
No
Interventions
Metformin
An extended release formulation will be used which improves compliance and reduces GI side effects.
Placebo
Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
Locations (2)
Atrium Health Sanger Heart and Vascular Clinic Institute
Charlotte, North Carolina, United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, United States